File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.oraloncology.2013.12.011
- Scopus: eid_2-s2.0-84900488822
- PMID: 24440146
- WOS: WOS:000335889000002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma
Title | Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma |
---|---|
Authors | |
Keywords | EBER1 Distant metastasis BamH1-W TaqMan quantitative real time PCR Plasma EBV DNA Local recurrence Nasopharyngeal Cancer Head and Neck cancer Epstein-Barr virus EBNA1 |
Issue Date | 2014 |
Citation | Oral Oncology, 2014, v. 50, n. 6, p. 527-538 How to Cite? |
Abstract | Elevated levels of circulating cell-free Epstein-Barr virus (EBV) DNA have been detected in plasma and serum samples from nasopharyngeal cancer (NPC) patients by quantitative real time PCR (qPCR) test. This qPCR test for circulating EBV DNA was found to be useful in the clinical management of NPC patients. For instance, EBV DNA qPCR test has good sensitivity and specificity in the detection of NPC at disease onset. Increase of the viral DNA load was found in NPC patients at late stages of disease. High EBV DNA load at disease onset or detectable viral load post-treatment was associated with poor survival or frequent relapse in NPC patients. Residual EBV DNA load after primary treatment could be a useful indicator to justify adjuvant chemotherapy. The qPCR test might also be applied to define a poor prognostic group in patients at early stage (I/II) for implementing concurrent chemo-radiotherapy (chemo-RT) to improve patients' outcome. The test is also useful to monitor distant metastases or response to radiotherapy, chemo-RT or surgery. Supplementary tests, however, are needed to pick up EBV negative WHO type I NPC and test improvement is needed to increase sensitivity in detecting stage I disease and local recurrence. © 2013 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/251667 |
ISSN | 2023 Impact Factor: 4.0 2023 SCImago Journal Rankings: 1.257 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yip, Timothy T.C. | - |
dc.contributor.author | Ngan, Roger K.C. | - |
dc.contributor.author | Fong, Alvin H.W. | - |
dc.contributor.author | Law, Stephen C.K. | - |
dc.date.accessioned | 2018-03-08T05:00:37Z | - |
dc.date.available | 2018-03-08T05:00:37Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Oral Oncology, 2014, v. 50, n. 6, p. 527-538 | - |
dc.identifier.issn | 1368-8375 | - |
dc.identifier.uri | http://hdl.handle.net/10722/251667 | - |
dc.description.abstract | Elevated levels of circulating cell-free Epstein-Barr virus (EBV) DNA have been detected in plasma and serum samples from nasopharyngeal cancer (NPC) patients by quantitative real time PCR (qPCR) test. This qPCR test for circulating EBV DNA was found to be useful in the clinical management of NPC patients. For instance, EBV DNA qPCR test has good sensitivity and specificity in the detection of NPC at disease onset. Increase of the viral DNA load was found in NPC patients at late stages of disease. High EBV DNA load at disease onset or detectable viral load post-treatment was associated with poor survival or frequent relapse in NPC patients. Residual EBV DNA load after primary treatment could be a useful indicator to justify adjuvant chemotherapy. The qPCR test might also be applied to define a poor prognostic group in patients at early stage (I/II) for implementing concurrent chemo-radiotherapy (chemo-RT) to improve patients' outcome. The test is also useful to monitor distant metastases or response to radiotherapy, chemo-RT or surgery. Supplementary tests, however, are needed to pick up EBV negative WHO type I NPC and test improvement is needed to increase sensitivity in detecting stage I disease and local recurrence. © 2013 Elsevier Ltd. All rights reserved. | - |
dc.language | eng | - |
dc.relation.ispartof | Oral Oncology | - |
dc.subject | EBER1 | - |
dc.subject | Distant metastasis | - |
dc.subject | BamH1-W | - |
dc.subject | TaqMan quantitative real time PCR | - |
dc.subject | Plasma EBV DNA | - |
dc.subject | Local recurrence | - |
dc.subject | Nasopharyngeal Cancer | - |
dc.subject | Head and Neck cancer | - |
dc.subject | Epstein-Barr virus | - |
dc.subject | EBNA1 | - |
dc.title | Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.oraloncology.2013.12.011 | - |
dc.identifier.pmid | 24440146 | - |
dc.identifier.scopus | eid_2-s2.0-84900488822 | - |
dc.identifier.volume | 50 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 527 | - |
dc.identifier.epage | 538 | - |
dc.identifier.eissn | 1879-0593 | - |
dc.identifier.isi | WOS:000335889000002 | - |
dc.identifier.issnl | 1368-8375 | - |